SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
UC Davis has been activated as a clinical trial site for CERo Therapeutics' first-in-human Phase 1/1b CERTAIN-T study of CER-1236 in hematologic malignancies. UC Davis is also the primary manufacturing site for CER-1236, so the activation is expected to expand patient recruitment and shorten the time between cell manufacturing and infusion. The announcement was issued by SRX Global (SRXH), which signed a definitive agreement on October 7, 2026 to acquire CERo Therapeutics; the deal remains subject to closing conditions.
Key figures
- Drug Name
- CER-1236
- Phase Of Trial
- Phase 1/1b
- Dlt window days
- 28
- Patients dosed reported
- 6
- Transplant days post infusion
- 71
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.